Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs

@article{Norman2014UpdateOT,
  title={Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs},
  author={P. Norman},
  journal={Expert Opinion on Investigational Drugs},
  year={2014},
  volume={23},
  pages={55 - 66}
}
  • P. Norman
  • Published 2014
  • Medicine
  • Expert Opinion on Investigational Drugs
    • Introduction: The identification of PGD2 as the cognate ligand for the DP2 (formerly CRTH2) receptor and the apparent role of that receptor in allergic disease has led to considerable interest in the development of DP2 receptor antagonists for the treatment of asthma. Around 20 DP2 receptor antagonists have progressed into development. Areas covered: The DP2 antagonists in clinical development and those whose development has been discontinued are discussed in detail. This article highlights the… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    35 Citations
    Highly Influencial Citations
    1
    Background Citations
    12

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

        35 Citations
        Citation Type

        Citation Type

        Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma
        • 27
        Investigational prostaglandin D2 receptor antagonists for airway inflammation
        • 17
        • Highly Influenced
        Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives
        • 18
        Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy
        • 33
        • PDF
        Fevipiprant ( QAW 039 ) , a Slowly Dissociating CRTh 2 Antagonist with the Potential for Improved Clinical Efficacy s
        • PDF
        Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists in asthma: a systematic review and meta-analysis protocol
        • 4
        • PDF
        Synthesis and preclinical evaluation of the CRTH2 antagonist [11C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass.
        • 3
        • PDF
        New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial
        • PDF
        Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
        • 12
        The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
        • 63

        References

        SHOWING 1-10 OF 64 REFERENCES
        DP2 receptor antagonists in development
        • P. Norman
        • Medicine
        • Expert opinion on investigational drugs
        • 2010
        • 46
        The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma
        • 4
        Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
        • 260
        International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
        • 327
        • Highly Influential
        • PDF
        Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
        • 76
        Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma
        • 19
        Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.
        • 21
        • PDF
        Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview
        • 31
        Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation
        • 18
        • PDF
        Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators
        • 11